WegovysemaglutideClinical comparison in SpainWegovysemaglutide 
Mounjarotirzepatide
Ozempicsemaglutide
Wegovy vs Mounjaro vs Ozempic
WegovysemaglutideMounjarotirzepatideOzempicsemaglutideWhich is the right pathway?
- Different indications: they are not interchangeable versions of one medicine.
- Different mechanisms: semaglutide acts at GLP-1; tirzepatide acts at GIP and GLP-1.
- Different dose ladders: the milligram numbers cannot be compared directly.
- Individual choice: safety, diabetes status, response and tolerability matter.
- Prescription only: prescribing follows a medical assessment and is never automatic.
Answers at a glance
The questions patients usually ask first
Mounjaro in the direct trial
SURMOUNT-5 reported −20.2% with tirzepatide versus −13.7% with semaglutide at week 72. Individual results vary.
Both Wegovy and Mounjaro
Both have authorised EU weight-management indications when BMI and health criteria are met.
No universal winner
Both require contraindication review, gradual escalation and monitoring. Personal history changes the balance.
It depends on the person
Gastrointestinal effects occur with both medicines and are most common during dose escalation.
Strength and product matter
Spanish pharmacy prices differ by presentation. Price must not drive an unsafe dose or inappropriate medicine.
Stock changes locally
Availability is controlled by pharmacies. A prescription does not guarantee stock of the prescribed strength.
It is a diabetes medicine
Ozempic is authorised for type 2 diabetes. Wegovy is the semaglutide presentation authorised for weight management.
Yes, with a clinical plan
The clinician reviews the last dose, timing, side effects and indication. Never overlap or double-dose.
Dense data comparison
Wegovy, Mounjaro and Ozempic compared
Slide across to compare
| Question | Wegovy | Mounjaro | Ozempic |
|---|---|---|---|
| Active ingredient | Semaglutide | Tirzepatide | Semaglutide |
| How it acts | GLP-1 receptor agonist | Dual GIP/GLP-1 receptor agonist | GLP-1 receptor agonist |
| Authorised EU pathway | Weight management | Weight management and type 2 diabetes | Type 2 diabetes |
| Usual frequency | Once weekly | Once weekly | Once weekly |
| Standard starting dose | 0.25 mg weekly | 2.5 mg weekly | 0.25 mg weekly |
| Common maintenance pathway | 2.4 mg weekly after escalation; individual exceptions apply | 5, 10 or 15 mg weekly after escalation | 0.5, 1 or 2 mg weekly for glycaemic control |
| Prescription required | Yes | Yes | Yes |
| Medicine bought separately | Yes | Yes | Yes |
Milligrams cannot be compared across different active ingredients. Wegovy and Ozempic share semaglutide but have different authorised uses, dose pathways and presentations.
Direct head-to-head evidence
SURMOUNT-5 compared tirzepatide and semaglutide
751 adults with obesity, or overweight plus a related condition, without type 2 diabetes were treated for 72 weeks using maximum tolerated doses. The study was funded by Eli Lilly.
72weeks751 participants
How to read this: these are study averages, not a promise. Trial eligibility, maximum tolerated doses, adherence and follow-up differ from everyday care. “More average weight loss” does not automatically mean “safer” or “better” for one individual.
Why the dose numbers diverge
Three different dose ladders
Wegovysemaglutide for weight management
0.250.511.72.4 mg
Standard escalation is gradual over 16 weeks. A doctor may delay escalation or maintain a tolerated dose according to response and side effects.
Mounjarotirzepatide
2.557.51012.515 mg
Increases use 2.5 mg steps after at least four weeks. Authorised maintenance doses are 5, 10 and 15 mg.
Ozempicsemaglutide for type 2 diabetes
0.250.512 mg
The dose ladder is designed for glycaemic control in type 2 diabetes. Sharing an ingredient with Wegovy does not make the products interchangeable.
Safety and tolerability
What overlaps—and what needs individual review
Common with both pathways
- Nausea, diarrhoea, vomiting or constipation
- Indigestion, abdominal discomfort and reduced appetite
- Symptoms may be stronger during dose escalation
- Dehydration can worsen kidney problems
- Gallbladder disease and pancreatitis require medical attention
Semaglutide-focused review
- Diabetic retinopathy risk matters in people with diabetes
- Current product information includes NAION eye-warning advice
- Wegovy and Ozempic doses must not be treated as equivalent
- Pregnancy planning requires stopping well in advance under medical advice
Tirzepatide-focused review
- Dual GIP/GLP-1 mechanism and its own escalation pathway
- Severe gastrointestinal disease or gastroparesis needs caution
- Hypoglycaemia risk increases with insulin or sulphonylureas
- Pregnancy planning requires stopping under medical advice
Seek urgent medical carefor severe persistent abdominal pain, repeated vomiting with inability to keep fluids down, breathing difficulty, facial or throat swelling, collapse or another life-threatening symptom. Call 112 in Spain.
Switching treatment
Wegovy ↔ Mounjaro
There is no universal manufacturer-endorsed waiting interval that is correct for every patient. A switching plan must account for the previous product, last injection date, current dose, side effects, reason for switching, diabetes treatment and other medicines.
- Do not overlap weekly injections.
- Do not translate one medicine’s milligrams into the other.
- A lower starting dose may be needed even after higher-dose treatment.
- Persistent side effects may require a longer pause and examination.
WegovyMounjaroFrom screening to pharmacy📅 🩺 ▦
Four clear steps
Complete the free pre-check
Basic eligibility and safety screening identifies the correct appointment route. The doctor makes the final prescribing decision.
Book consultation
Choose an available €39 telephone or video appointment.
Doctor review
Discuss indication, history, medicines, risks, goals and monitoring.
Plan and e-prescription
If suitable, receive a REMPe QR prescription and use it at a pharmacy.
Medicine is purchased separately. Prescribing is not guaranteed.
Detailed questions
Wegovy, Mounjaro and Ozempic questions
Which causes more average weight loss?
SURMOUNT-5 reported greater mean weight loss with tirzepatide than semaglutide at 72 weeks, but results do not predict one person’s outcome.
Which is safest?
No medicine is universally safest. Medical history, other medicines, diabetes, eye health, gastrointestinal disease and individual tolerability all matter.
Which causes less nausea?
Both can cause nausea, particularly while escalating. Individual tolerability and the rate of escalation often matter more than the brand name.
Why can’t Ozempic simply replace Wegovy?
Although both contain semaglutide, Ozempic is authorised for type 2 diabetes and Wegovy for weight management. Their presentations and dose pathways differ.
Why do Ozempic and Wegovy doses diverge?
The products were developed and authorised for different indications and outcomes. The dose is tied to the product’s approved pathway, not merely the active ingredient.
Can the doctor prescribe Ozempic for weight loss?
Ozempic is not authorised as a general weight-management medicine. Any prescribing outside an authorised indication is an individual clinical and legal decision; this service does not promise it routinely.
Which is cheaper in Spain?
It depends on product and strength. Review the current Wegovy and Mounjaro price guides and confirm the exact pharmacy price.
Why might Ozempic appear cheaper?
Its authorised diabetes presentations and pricing pathway differ from Wegovy. A lower price does not make it an interchangeable weight-management treatment.
Which is more available?
Supply changes by medicine, strength and pharmacy. Neither a consultation nor a prescription guarantees local stock.
Are serious side effects different?
There is substantial overlap, including pancreatitis, gallbladder problems, dehydration and severe allergic reactions. Each product also has label-specific warnings that the doctor reviews.
How long do I wait when switching?
There is no single interval for everyone. The clinician reviews the last injection, current dose, side effects and reason for switching before setting the date and starting dose.
Can I take both together?
No. Do not overlap or combine these weekly treatments unless explicitly directed within a specialist clinical plan.
Does €39 include the pen?
No. It covers the medical consultation; prescribed medicine is purchased separately from the pharmacy.
Which is most proven?
All have substantial clinical programmes for their authorised uses. “Most proven” depends on the condition and outcome being discussed, not brand popularity.
Medical review
Reviewed byDr Ben Harry Clegg
GP · Málaga registration 292911940 · Medical services registration NICA 55712 · Medically reviewed 28 August 2026.
Sources checked 28 August 2026: EMA — Wegovy product information · EMA — Mounjaro product information · EMA — Ozempic product information · SURMOUNT-5 head-to-head trial · ClinicalTrials.gov NCT05822830.
Medically reviewed
Dr Ben Harry Clegg
General practitioner · Málaga registration 292911940 · Nerja Medical Center NICA 55712
Meet the telehealth medical team